BRISTOL MYERS SQUIBB CO
BMYAPI behind this page
BMY Q3 2025 request
Playground key active
/api/financials?ticker=BMY&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 12,222 | 11,892 | +2.8% |
Show Product Lines breakouts |
|||
| Abecma | 137 | 124 | +10.5% |
| Abraxane | 74 | 253 | -70.8% |
| Alliance and other revenues | 372 | 409 | -9.0% |
| Alliance revenues | 125 | 105 | +19.0% |
| Alliance revenues · Collaborative Arrangement | 125 | 105 | +19.0% |
| Breyanzi | 359 | 224 | +60.3% |
| Camzyos | 296 | 156 | +89.7% |
| Cobenfy | 43 | — | — |
| Eliquis | 3,746 | 3,002 | +24.8% |
| Gross product sales | 22,494 | 21,223 | +6.0% |
| Growth Portfolio | 6,857 | 5,812 | +18.0% |
| Krazati | 53 | 34 | +55.9% |
| Legacy Portfolio | 5,365 | 6,080 | -11.8% |
| Net product sales | 11,850 | 11,483 | +3.2% |
| Net product sales · Collaborative Arrangement | 3,755 | 3,091 | +21.5% |
| Opdivo | 2,532 | 2,360 | +7.3% |
| Opdivo Qvantig | 67 | — | — |
| Opdualag | 299 | 233 | +28.3% |
| Orencia | 964 | 936 | +3.0% |
| Other Growth products | 514 | 443 | +16.0% |
| Other Legacy products | 177 | 225 | -21.3% |
| Other revenues | 247 | 304 | -18.8% |
| Pomalyst/Imnovid | 675 | 898 | -24.8% |
| Reblozyl | 615 | 447 | +37.6% |
| Revlimid | 575 | 1,412 | -59.3% |
| Sotyktu | 80 | 66 | +21.2% |
| Sprycel | 119 | 290 | -59.0% |
| Yervoy | 739 | 642 | +15.1% |
| Zeposia | 161 | 147 | +9.5% |
Show Geography breakouts |
|||
| Non Us | 3,602 | 3,389 | +6.3% |
| Other | 290 | 271 | +7.0% |
| US | 8,329 | 8,232 | +1.2% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 3,880 | 3,196 | +21.4% |
| Cost of Revenue | 3,435 | 2,957 | +16.2% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 1,851 | 1,496 | +23.7% |
| Selling, General & Administrative | 1,789 | 1,983 | -9.8% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 62 | 76 | -18.4% |
| Research & Development | 2,528 | 2,374 | +6.5% |
Show Nature Of Expense breakouts |
|||
| Drug Development | 1,151 | 1,094 | +5.2% |
| Other | 1,063 | 957 | +11.1% |
| Research | 313 | 323 | -3.1% |
| Acquired I P R D | 633 | 262 | +141.6% |
| Amortizationof Acquired Intangible Assets | 831 | 2,406 | -65.5% |
| Other Non-Operating Income (Expense) | -108 | 234 | -146.2% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 11 | -12 | +191.7% |
| Total Costs & Expenses | 9,108 | 10,216 | -10.8% |
| Income Before Taxes | 3,114 | 1,676 | +85.8% |
| Income Tax Expense (Benefit) | 919 | 461 | +99.3% |
| Net Income | 2,195 | 1,215 | +80.7% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | -6 | 4 | -250.0% |
| Retained Earnings | 2,201 | 1,211 | +81.8% |
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | -6 | 4 | -250.0% |
| Net Income | 2,201 | 1,211 | +81.8% |
| EPS (Basic) | 1.08 | 0.6 | +80.0% |
| EPS (Diluted) | 1.08 | 0.6 | +80.0% |
| Interest Expense | 480 | 505 | -5.0% |
| Interest Income | -161 | -94 | -71.3% |
| Comprehensive Income | 2,242 | 1,199 | +87.0% |
| Wtd Avg Shares (Basic) | 2,036 | 2,028 | +0.4% |
| Wtd Avg Shares (Diluted) | 2,039 | 2,031 | +0.4% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 24 | -133 | +118.0% |
| Income Loss From Equity Method Investments | 6 | 23 | -73.9% |
| Gain Loss On Investments | -190 | -12 | -1483.3% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 15,726 | 7,890 | +99.3% |
| Available For Sale Securities Debt Securities Current | 776 | 204 | +280.4% |
| Receivables Net Current | 11,422 | 11,026 | +3.6% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 198 | 190 | +4.2% |
| Inventory | 2,758 | 3,332 | -17.2% |
| Other Assets Current | 4,948 | 5,623 | -12.0% |
| Total Current Assets | 35,630 | 28,075 | +26.9% |
| Accounts Receivable | 9,624 | 9,317 | +3.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 7,349 | 6,903 | +6.5% |
| Goodwill | 21,745 | — | — |
| Deferred Tax Assets | 4,961 | 3,609 | +37.5% |
| Available For Sale Securities Debt Securities Noncurrent | 406 | 324 | +25.3% |
| Other Non-Current Assets | 6,332 | 6,044 | +4.8% |
| Total Assets | 96,889 | 93,670 | +3.4% |
| Operating Lease Right-of-Use Assets | 1,604 | — | — |
Show Lease Contractual Term breakouts |
|||
| Commencement of San Diego Lease | 370 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 20,465 | 26,964 | -24.1% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Acquired marketed product rights | 11,036 | 16,387 | -32.7% |
| Computer Software Intangible Asset | 372 | 415 | -10.4% |
| Technology Based Intangible Assets | 1,457 | 1,787 | -18.5% |
Show Indefinite Lived Intangible Assets By Major Class breakouts |
|||
| In Process Research And Development | 7,600 | 8,375 | -9.3% |
| Current Liabilities | |||
| Debt Current | 4,509 | 1,078 | +318.3% |
| Accounts Payable | 4,288 | 3,469 | +23.6% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 2,141 | 1,455 | +47.1% |
| Other Liabilities Current | 19,339 | 18,091 | +6.9% |
| Total Current Liabilities | 28,136 | 22,638 | +24.3% |
| Current Portion of Long-Term Debt | 4,248 | 873 | +386.6% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 225 | 430 | -47.7% |
| Long-Term Debt | 44,469 | 48,674 | -8.6% |
| Other Non-Current Liabilities | 5,459 | 4,728 | +15.5% |
| Total Liabilities | 78,289 | 76,470 | +2.4% |
| Long-Term Debt | 48,717 | 49,547 | -1.7% |
| Operating Lease Liabilities | 1,849 | 1,483 | +24.7% |
| Accrued Income Taxes Noncurrent | 1,739 | 1,543 | +12.7% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 292 | 292 | 0.0% |
| Additional Paid-In Capital | 46,265 | 45,896 | +0.8% |
| Accumulated Other Comprehensive Income | -1,513 | -1,468 | -3.1% |
| Retained Earnings | 17,093 | 16,097 | +6.2% |
| Treasury Stock Common Value | -43,586 | — | — |
| Total Stockholders' Equity | 18,552 | — | — |
| Minority Interest | 48 | 58 | -17.2% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18,600 | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,513 | -1,468 | -3.1% |
| Additional Paid In Capital | 46,265 | 45,896 | +0.8% |
| Common Stock | 292 | 292 | 0.0% |
| Noncontrolling Interest | 48 | 58 | -17.2% |
| Retained Earnings | 17,093 | 16,097 | +6.2% |
| Treasury Stock Common | -43,586 | -43,675 | +0.2% |
| Total Liabilities & Equity | 96,889 | 93,670 | +3.4% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 3,034 | 7,720 | -60.7% |
| Deferred Income Taxes | -573 | -1,298 | +55.9% |
| Stock-Based Compensation | 420 | 387 | +8.5% |
| Impairment Of Long Lived Assets To Be Disposed Of | 514 | 1,010 | -49.1% |
| Divestituregainsandroyalties | -880 | -838 | -5.0% |
| Equity Method Investment Realized Gain Loss On Disposal | -90 | -221 | +59.3% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 336 | — | — |
Show Contingent Consideration By Type breakouts |
|||
| Contingent value rights | 336 | — | — |
| Other Non-Cash Items | -76 | 123 | -161.8% |
| Increase Decrease In Receivables | -314 | 121 | -359.5% |
| Change in Inventory | -255 | -661 | +61.4% |
| Change in Accounts Payable | 88 | -333 | +126.4% |
| Increase Decrease In Other Accrued Liabilities | 1,957 | 1,889 | +3.6% |
| Increase Decrease In Accrued Income Taxes Payable | 320 | -1,381 | +123.2% |
| Increase Decrease In Other Operating Capital Net | -597 | -101 | -491.1% |
| Net Cash from Operations | 12,182 | 10,751 | +13.3% |
| Investing Activities | |||
| Proceeds From Sale And Maturity Of Available For Sale Securities | 1,573 | 1,060 | +48.4% |
| Payments To Acquire Marketable Securities | -1,922 | -398 | -382.9% |
| Proceeds From Sale Of Equity Securities Fv Ni | 61 | 60 | +1.7% |
| Capital Expenditures | -941 | -870 | -8.2% |
| Divestitureandotherproceeds | 792 | 766 | +3.4% |
| Payments To Acquire Businesses Net Of Cash Acquired | -2,237 | -21,774 | +89.7% |
| Net Cash from Investing | -2,674 | -21,156 | +87.4% |
| Financing Activities | |||
| Proceeds From Other Short Term Debt | 431 | 504 | -14.5% |
| Repayments Of Long Term Debt | -872 | -2,873 | +69.6% |
| Payments Of Dividends | -3,783 | -3,645 | -3.8% |
| Payments For Proceeds From Stock Option Exercises And Other Adjustments | -95 | -87 | -9.2% |
| Net Cash from Financing | -4,319 | 6,769 | -163.8% |
| Supplemental | |||
| Income Taxes Paid | 2.2 | 3.1 | -29.0% |
| Interest Paid | 1.7 | 1.4 | +21.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 190 | 10 | +1800.0% |
| Net Change in Cash | 5,379 | -3,626 | +248.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 15,726 | 7,893 | +99.2% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.